TELO Stock — Telomir Pharmaceuticals Inc.: Cash, EV, Pipeline

Share price

$1.23

Market cap

$84.6M

Cash

$5.2M

Enterprise value

$79.4M

Balance sheet

Cash	$5.2M
Debt	$0.0M
Net cash	$5.2M
Enterprise value	$79.4M
Basic shares	68.8M shares
Fully diluted shares	75.9M shares
Fully diluted market cap	$93.4M
Cash per share	$0.08

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading TELO daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Jun 12 - Jul 24	Zn-Telomir	Phase 2	Triple-Negative Breast Cancer (TNBC); Advanced Triple-Negative Breast Cancer; Metastatic Triple-negative Breast Cancer	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Telomir-Zn

Preclinical · Active Modality: small molecule (oral)

Aliases Telomir-1

Partnerships MIRALOGX, LLC (two exclusive license agreements, November 2022 and March 2025; 8% royalty on net sales plus minimum annual royalty; worldwide rights obtained following the March 2026 merger)

Indications

Advanced or metastatic triple-negative breast cancer (Preclinical)
Wilson's disease (Preclinical)
Other oncology and metabolic indications (prostate, pancreatic cancers; diabetes) under preclinical evaluation (Preclinical)

Catalysts

— 2026

Status note Lead investigational candidate. All findings to date are preclinical. Company plans to submit an IND in 2026 and, if effective, commence a Phase 1/2 clinical trial thereafter, subject to regulatory review and manufacturing/operational readiness.

Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Zn-Telomir
Lead indication	Triple-Negative Breast Cancer (TNBC)
Lead phase	Phase 2
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07581314	Phase 2	Not yet recruiting	Sponsor	TELO	—	Triple-Negative Breast Cancer (TNBC); Advanced Triple-Negative Breast Cancer; Metastatic Triple-negative Breast Cancer	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for Telomir Pharmaceuticals, Inc. on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

TELO — Telomir Pharmaceuticals Inc.